NasdaqGS:ERASBiotechs
A Look At Erasca (ERAS) Valuation After Securing Global Rights To ERAS-0015
Why ERAS-0015 is at the center of the story
Erasca (ERAS) has just exercised its option to secure worldwide rights to its pan RAS molecular glue ERAS-0015 by expanding its license with Joyo Pharmatech to cover China, Hong Kong, and Macau.
This follows a recent clinical trial collaboration with Tango Therapeutics involving ERAS-0015 and increased analyst attention tied to upcoming Phase 1 data, which helps explain why the stock is attracting more investor focus.
See our latest analysis for...